Catalan biotech company Aniling, a member of Catalonia.health, has announced a strategic collaboration with Illumina to advance unified genomic and epigenetic assays in oncology.
The collaboration will integrate Aniling’s proprietary GEUS (Genetic and Epigenetic Unified Sequencing) technology with Illumina’s sequencing platforms, enabling the simultaneous analysis of genomic and epigenetic biomarkers within a single workflow.
This combined approach is expected to generate more comprehensive multiomic data, supporting a deeper understanding of cancer biology and contributing to the advancement of precision medicine.
In addition, the partnership aims to strengthen the reach and robustness of Aniling’s solutions while fostering innovation in oncology research through streamlined integration and interpretation of complex data.
This milestone reinforces the company’s strategy to expand its presence in advanced molecular diagnostics and to accelerate the adoption of multiomic approaches in both clinical and research settings.
Comments